Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Leukemia Research|February 25, 2009
Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cellsRobert T O'Donnell, David Pearson, Hayes C McKnight, et al.
Cancer Immunology, Immunotherapy : CII|March 19, 2009
Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacyRobert T O'Donnell, David Pearson, Hayes C McKnight, et al.
Molecular Medicine (Cambridge, Mass.)|September 1, 2015
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt LymphomaYanGuo Kong, Gustavo A Barisone, Ranjit S Sidhu, et al.
Investigational New Drugs|March 24, 2009
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)Robert T O'Donnell, Shiloh M Martin, Yunpeng Ma, et al.
Journal of Autoimmunity|November 7, 2002
Phosphorylation abnormalities: NZB mice exhibit a B-cell signalling defectJoseph M Tuscano, Tom C Hsu, Hayes McKnight, et al.
Leukemia Research|October 9, 2012
Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemiaJason Kato, Noriko Satake, Robert T O'Donnell, et al.
International Journal of Molecular Sciences|July 27, 2024
Fermented Wheat Germ Protein with Histone Deacetylase Inhibitor AR42 Demonstrates Enhanced Cytotoxicity against Lymphoma Cells In Vitro and In VivoJoshua F Meckler, Daniel J Levis, Yanguo Kong, et al.
Leukemia Research|September 22, 2014
Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7YanGuo Kong, Gustavo A Barisone, Mastewal Abuhay, et al.
Animal Models and Experimental Medicine|July 3, 2020
Alcohol-induced Wnt signaling inhibition during bone fracture healing is normalized by intermittent parathyroid hormone treatmentEsha M Kapania, Taylor J Reif, Aaron Tsumura, et al.
Leukemia & Lymphoma|December 27, 2013
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium StudyMark H Kirschbaum, Kenneth A Foon, Paul Frankel, et al.
Pageof 7